

Nemaura Medical Inc

09:41 05 Dec 2019

Nemaura Medical unveils Type 2 diabetes management app as companion to its SugarBEAT glucose monitor

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the SugarBEAT continuous glucose monitor, has launched a new app to help patients prevent and reverse Type 2 diabetes.

The digital health offering, BEAT diabetes, encourages beneficial behavioral change through a range of monitoring and coaching services. The full range of subscription-based services includes an app that makes lifestyle recommendations based on blood glucose levels, offers one-on-one coaching and routinely measures other parameters that allow improved disease management.

"We believe that simple monitoring of glucose is not enough," CEO Faz Chowdhury said in a statement. Patients need access to a variety of methods to better manage their glucose. The combination of our self-monitoring wearable platform with digital support and prompts, as well as one-on-one coaching through the BEAT diabetes app is designed to provide greater optionality and flexibility to both patients and payors alike."

READ: Nemaura announces 1-for-10 reverse stock split to attract institutional investors

The new BEAT diabetes website allows individuals and corporate users to register early interest, so Nemaura can provide details about what subscription packages will be available.

Combining the app with patient coaching has been proven to enhance the impact of diabetes management, the company said. Both BEAT diabetes and the SugarBEAT monitor itself serve the underserved \$69 billion market for Type 2 diabetics and \$50 billion market for pre-diabetics.

The Loughborough, England company's SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. What's unique about SugarBEAT is its skin-patch technology, which the company said offers for painless glucose management.


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 3.14

Market Cap: \$65.34 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: NMRD

Listing: NASDAQ

52 week	High	Low
	14.5	2.5

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).